Actual Stock Price

Analyst Coverage

Today, Nyxoah is covered by 9 financial analysts.

Contact information

Degroof Petercam

Laura Roba (l.roba@degroofpetercam.com)

Kepler Cheuvreux

Jon Berggren (jberggren@keplercheuvreux.com)

Wolfe Research

Mike Polark, CFA (mpolark@wolferesearch.com)

Cantor Fitzgerald

Ross Osborn (ross.osborn@cantor.com)

Adam Maeder

adam.maeder@psc.com

Jonathan Block

blockj@stifel.com

Oppenheimer

Suraj Kalia (suraj.kalia@opco.com)

H.C. Wainwright

Edward White (ewhite@hcwco.com)

Baird

David Rescott (drescott@rwbaird.com)

All rights reserved © 2021 Nyxoah SA. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah SA. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020

Privacy Notice
Cookie Policy
 Cookie Settings
bubble
bubble
bubble
bubble
bubble